← boardnext 2029-08
MBRX
Moleculin Biotech, Inc.distress 8/10 · high distress / dilution risk$2.100%today-90% from 52w high
Lead: relapsed/refractory acute myeloid leukemia · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$10M
Runway
0.4 yrs
Shares 1y
-82%
Price & events
-56.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-3.2%
1W
-23.6%
1M
-17.3%
3M
-55.1%
6M
-88.2%
1Y
-97.6%
2Y
-99.8%
5Y
-99.9%
All
Overview
- Market Cap
- $11.21M
- Volume
- 5.60K
- 52 Week Range
- $1.96 – $20.90
- Total Shares
- 5.34M
- Float Shares
- 5.29M
- Short %
- 20.14%
- % Held by Insiders
- 0.63%
- % Held by Institutions
- 3.33%
- RVOL
- 0.01x
- Beta
- 1.75
Pipeline stages · 1 programs
Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamyci
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2029-08 Estimated 50% readout ~2029-10-15 | Phase 2/3 | Liposomal Annamycin Injection in combination with Cytarabine Injection, Liposomal Annamyci | Acute Myeloid Leukaemia (AML) | — | recruiting |
Catalyst news & presentations · 4
- prior to June 30, 2026readoutPhase 2/3Annamycin · First unblinding of pivotal Phase 2B/3 MIRACLE trial dataSEC 8-K
- first quarter of 2026readoutPhase 2/3Annamycin · First planned interim unblinding of data from pivotal Phase 2B/3 MIRACLE study after completing treatment of first 45 subjects.SEC 8-K
- 2026-03-23enrollment completesecondaryPhase 2/3Annamycin · 45th subject enrolled in MIRACLE trialSEC 8-K
- 2025-11-12partnershipAnnamycin · Research and material transfer agreement with UNC for investigator-initiated preclinical research in pancreatic cancer.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+900% upside) · 3 analysts
- 2026-03-24HC Wainwright & Co.Buy
- 2025-12-11HC Wainwright & Co.Buy
- 2025-09-10HC Wainwright & Co.Buy
- 2025-08-27HC Wainwright & Co.Buy
- 2025-06-18HC Wainwright & Co.Buy
- 2025-03-25Maxim GroupHold → Buy
Competitors — relapsed/refractory acute myeloid leukemia
Recent news
- 2026-07-12Enterprise value to revenue forward of Moleculin Biotech, Inc. – GETTEX:MOL0 - TradingView
- 2026-07-08Price to earnings forward of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
- 2026-07-07Moleculin Biotech focuses on oncology pipeline and Nasdaq listing - Ad-hoc-news.de
- 2026-07-06Moleculin Biotech CEO Discusses Preliminary MIRACLE Trial Results for Annamycin in Virtual Investor Segment - Quiver Quantitative
- 2026-07-06Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment - GlobeNewswire
- 2026-07-06Moleculin CEO discusses preliminary results from leukemia trial - Investing.com
- 2026-07-06Moleculin Biotech (MBRX) Shares Slide 9% as Stock Approaches Key Support Level - MESA MA - dars.gov.et
- 2026-07-06Moleculin says early MIRACLE trial data support Annamycin in leukemia - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.